Gilead Sciences, after trial win, moves ahead with $247M settlement in HIV antitrust case

Even after Gilead Sciences and Teva Pharmaceutical Industries prevailed in a high-stakes HIV drug antitrust trial over the summer, Gilead appears ready to hand over hundreds of millions of dollars to resolve part of the wide-ranging case.